BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) released its earnings results on Wednesday. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15, FiscalAI reports. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. During the same quarter in the previous year, the business earned $0.15 earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue rose 10% year over year to $158.2 million on a comparable basis, with continued new-prescriber additions, stable demand and an improved paid rate of 84%.
• The pediatric ORLADEYO pellets launch has begun strongly, with 47 prescriptions received by July 31—above the company’s full-year expectation—and early payer approvals and physician interest described as encouraging.
• BioCryst completed enrollment in the pivotal ALPHA-ORBIT trial of long-acting injectable navenibart ahead of schedule; top-line data are expected in the third quarter of 2027.
• The company raised 2026 total revenue guidance to $690 million-$715 million and lowered non-GAAP operating-cost guidance to $420 million-$440 million, supported by $113.2 million in second-quarter operating profit and more than $350 million in cash and investments.
• BioCryst is shutting down its Birmingham research unit and discontinuing internal discovery programs, shifting to externally sourced assets; management expects lower costs but must establish a stronger pipeline through future business-development transactions.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded up $0.07 during midday trading on Wednesday, hitting $9.09. 3,757,980 shares of the company were exchanged, compared to its average volume of 4,992,015. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.22. The firm has a market capitalization of $2.31 billion, a P/E ratio of -5.10 and a beta of 0.55. The firm’s 50 day moving average price is $9.32 and its two-hundred day moving average price is $8.67.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BCRX. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wedbush lowered their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target for the company. Finally, Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in BCRX. Royal Bank of Canada boosted its stake in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after acquiring an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after acquiring an additional 640,704 shares in the last quarter. Caxton Associates LLP bought a new position in BioCryst Pharmaceuticals during the first quarter worth about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in BioCryst Pharmaceuticals by 11.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after purchasing an additional 47,355 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.